EGLN2 and breast cancer: In particular, its interaction with EglN2, an enzyme involved in the regulation of the hypoxia-inducible factor (HIF) pathway, appears to be central to the modulation of mitochondrial function and has been implicated in BC tumorigenesis (182, 183).